Thirty years ago, Parkinson disease was described as a shortage of the neurotransmitter dopamine. Today, understanding of this disorder includes possible genetic influences, premorbid and nonmotor issues, and a variety of neurologic, cognitive, and psychiatric symptoms. Using a case study, this article presents the current science of Parkinson disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NPR.0000453646.44157.83 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of intraoperative monitoring in target selection in deep brain stimulation: A single centre study.
Clin Park Relat Disord
January 2025
Department of Neurology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
Introduction: Intraoperative microelectrode recording (MER) and intraoperative test stimulation may provide vital information for optimal electrode placement and clinical outcome in movement disorders patients treated with deep brain stimulation (DBS). The aims of this retrospective study were to determine (i) how often the planned (imaging based) placements of electrodes were changed due to MER and intraoperative test stimulation in Parkinson's disease (PD), dystonia and essential tremor (ET) patients; (ii) whether the frequency of repositioning changed over time; (iii) whether patients' age or disease duration (in PD) influenced the frequency of repositioning.
Methods: Data on the planned and the final placement of 141 electrodes in 72 consecutive DBS treated patients (52 PD, 11 dystonia, 9 ET) was collected over the first 8 years of DBS implementation in a single center.
Novel strategies targeting mitochondria-lysosome contact sites for the treatment of neurological diseases.
Front Mol Neurosci
January 2025
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Mitochondria and lysosomes are critical for neuronal homeostasis, as highlighted by their dysfunction in various neurological diseases. Recent studies have identified dynamic membrane contact sites between mitochondria and lysosomes, independent of mitophagy and the lysosomal degradation of mitochondrial-derived vesicles (MDVs), allowing bidirectional crosstalk between these cell compartments, the dynamic regulation of organelle networks, and substance exchanges. Emerging evidence suggests that abnormalities in mitochondria-lysosome contact sites (MLCSs) contribute to neurological diseases, including Parkinson's disease, Charcot-Marie-Tooth (CMT) disease, lysosomal storage diseases, and epilepsy.
View Article and Find Full Text PDFTranscutaneous vagus nerve stimulation for Parkinson's disease: a systematic review and meta-analysis.
Front Aging Neurosci
January 2025
Affiliated Rehabilitation Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Background: Transcutaneous vagus nerve stimulation (tVNS) has emerged as a novel noninvasive adjunct therapy for advanced Parkinson's disease (PD), yet no quantitative analysis had been conducted to assess its therapeutic effect.
Objectives: This review aimed to investigate the efficacy of tVNS on motor function, other potential clinical targets and its safety in various treatment conditions.
Methods: We searched six databases for randomized controlled trials (RCTs) that involved treating PD patients with tVNS.
The Characteristics of the Metabolomic Profile in Patients with Parkinson's Disease and Vascular Parkinsonism.
Acta Naturae
January 2024
Novosibirsk State University, Novosibirsk, 630090 Russian Federation.
The gradually increasing age of the world population implies that the prevalence of neurodegenerative diseases also continues to rise. These diseases are characterized by a progressive loss of cognitive and motor functions. Parkinson's disease, which involves the gradual death of specialized neural tissue, is a striking example of a neurodegenerative process.
View Article and Find Full Text PDFBrain Age as a New Measure of Disease Stratification in Huntington's Disease.
Mov Disord
January 2025
School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.
Background: Despite advancements in understanding Huntington's disease (HD) over the past two decades, absence of disease-modifying treatments remains a challenge. Accurately characterizing progression states is crucial for developing effective therapeutic interventions. Various factors contribute to this challenge, including the need for precise methods that can account for the complex nature of HD progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!